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ValidationAbstract A simple and accurate method for the analysis of ibuprofen (IBU) and famotidine (FAM)
in their combined dosage form was developed using second order derivative spectrophotometery.
IBU and FAM were quantiﬁed using second derivative responses at 272.8 nm and 290 nm in the
spectra of their solutions in methanol. The calibration curves were linear in the concentration range
of 100–600 lg/mL for IBU and 5–25 lg/mL for FAM. The method was validated and found to be
accurate and precise. Developed method was successfully applied for the estimation of IBU and
FAM in their combined dosage form.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Ibuprofen (IBU) is chemically, (RS)-2-(4-(2-methylpropyl)
phenyl)propanoic acid (O’Neil, 2001). The empirical formula
of IBU is C13H18O2 and a molecular weight of 206.2 g/mole
(Fig. 1). It is a non steroidal anti-inﬂammatory drug and it
inhibits prostaglandin biosynthesis by blocking the enzyme
cyclooxygenase, which converts arachidonic acid to prostaglan-
din. It is used as analgesic, antipyretic and anti-inﬂammatory
drug (Rang and Dale, 2003). Famotidine (FAM) is chemically3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)
sulfanyl]-N0-sulfamoylpropanimidamide. It has an empirical
formula of C8H15N7O2S3 and a molecular weight of 337 g/mole
(Fig. 1). It is a histamine-2 receptor blocker. Histamine stimu-
lates cells lining of stomach to produce acid. Famotidine blocks
the action of histamine on stomach cells, thus reducing the
production of acid by the stomach (Rang and Dale, 2003).
Ibuprofen is used as anti-inﬂammatory and analgesic drug
while famotidine reduces gastric acid secretion. By combining
ibuprofen and famotidine, the gastrointestinal side effects pro-
duced by ibuprofen is reduced by famotidine without altering
its ability to reduce pain and inﬂammation. The combined for-
mulation is indicated for the treatment of rheumatoid arthritis
and osteoarthritis and to decrease the risk of developing upper
gastrointestinal ulcers.
Ibuprofen is ofﬁcial in Indian Pharmacopoeia, British
Pharmacopoeia and United state Pharmacopoeia. A literature
survey regarding quantitative analysis of these drugs revealed
Figure 1 Structure of (A) ibuprofen and (B) famotidine.
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for the estimation of ibuprofen alone and in combination with
other drugs by liquid chromatographic (LC) (Indian Pharma-
copoeia, 2007; British Pharmacopoeia, 2009; United States
Pharmacopoeia and National Formulary, 2004; Reddy and
Reddy, 2009), HPTLC (Chitlange et al., 2008; Sam Solomon
et al., 2010; Rele and Sawant, 2010), super critical ﬂuid chroma-
tography (Bari et al., 1997) and spectrophotometric methods
(Gondalia et al., 2010). Famotidine is ofﬁcial in British Phar-
macopoeia and United state Pharmacopoeia. Literature survey
revealed that liquid chromatographic (LC) (Sultana et al.,
2011), HPTLC (Novakovic´, 1999) and spectrophotometric
methods (Kanakapura et al., 2011) have been reported for
the estimation of famotidine.
There is no method reported for the estimation of IBU and
FAM in combined dosage form. Present study involves the
development and validation of second order derivative spec-
trophotometric method for the estimation of IBU and FAM




All the absorption spectra and derivative spectra were re-
corded on UV–visible double beam spectrophotometer (UV-
1700, Shimadzu Corp., Japan) with 1 cm quartz cell.
2.1.2. Electronic balance
All the drugs and chemicals were weighed on Shimadzu elec-
tronic balance (AX 200, Shimadzu Corp., Japan).
2.2. Reagents and materials
2.2.1. Pure samples
Analytically pure FAM and IBU were obtained as gift samples
from Blue Cross Laboratory Limited, Mumbai, India and
Mercury Laboratories Limited, Vadodara, India, respectively.
The purity of IBU and FAM were found to be 99.32%, and
99.45% respectively, according to the manufacturer’s analysis
certiﬁcates.2.2.2. Market samples
Tablet formulation (DUEXIS, Horizon Pharma, USA) con-
taining labeled amount of 800 mg of ibuprofen and 26.6 mg
of famotidine was used for the study.
2.2.3. Chemicals and reagents
Methanol (E. Merck, Mumbai, India) used as a solvent was of
analytical grade.
2.3. Second order derivative spectrophotometric method
2.3.1. Preparation of standard stock solutions
Stock solutions were prepared by weighing 25 mg each of IBU
and FAM and transferring to 2 separate 25 mL volumetric
ﬂasks. Volume was made up to the mark with methanol, which
gave 1000 lg/mL of both the drugs. Aliquot from the stock
solutions of FAM was appropriately diluted with methanol
to obtain the working standard of 100 lg/mL of FAM.
2.3.2. Selection of wavelengths
Working standard solutions of IBU and FAM were diluted
appropriately with methanol to obtain solution containing
100 lg/mL of IBU and 10 lg/mL of FAM. Spectra of above
solutions were scanned in the spectrum mode between 200
and 400 nm, with a bandwidth of 2 nm. These zero order spec-
tra of IBU and FAM were treated to obtain corresponding sec-
ond order derivative spectra with an interpoint distance of
8 nm and scaling factor of 100.
Using memory channels, the second order derivative spec-
tra were overlapped. The zero crossing point (ZCPs) values
of IBU at which the FAM showed derivative response were re-
corded. The wavelength of 290 nm was selected for the quan-
tiﬁcation of FAM (where the derivative response for IBU
was zero). Similarly, 272.8 nm was selected for the quantiﬁca-
tion of IBU (where the derivative response for FAM was zero).
Characteristic wavelengths (ZCPs) for IBU and FAM were
conﬁrmed by varying the concentration of both drugs.
2.3.3. Calibration curves for IBU and FAM
The working standard solutions of IBU and FAM were used
to prepare two different sets of diluted standards. Appropriate
aliquots of IBU and FAM working standard solutions were ta-
ken in different 10 mL volumetric ﬂasks and diluted up to the
mark with methanol to obtain ﬁnal concentrations in the range
of 100–600 lg/mL of IBU and 5–25 lg/mL of FAM, respec-
tively. Spectra of the solutions were scanned between 200
and 400 nm and were treated to obtain the corresponding sec-
ond order derivative spectra. Calibration curves were con-
structed relating the peak amplitude at 272.8 nm and at
290 nm to the corresponding concentrations and regression
equations were computed for IBU and FAM. All the spectro-
photometric estimations were carried out at controlled room
temperature (20–25 C).
2.3.4. Method validation
The method was validated as per ICH guidelines for accuracy,
precision, speciﬁcity and robustness by following procedure.
2.3.4.1. Accuracy. The accuracy of the method was determined
by calculating recoveries of IBU and FAM by the method of
Figure 3 Second order overlay spectra of ibuprofen and
famotidine.
Table 1 Regression analysis of calibration curve.
Parameter IBU FAM
Linearity (lg/mL) 100–600 5–25
Correlation coeﬃcient (r) 0.9992 0.9990
Slope of regression 0.001 0.0168
Standard deviation of slope 0.0002 0.0004
Intercept of regression 0.0214 0.0204
Standard deviation of intercept 0.009476 0.005783
Table 2 Summary of validation parameters.
Parameters IBU FAM
Detection limit (lg/mL) 31.27 1.13
Quantitation limit (lg/mL) 94.76 3.44
Accuracy (%) 99.86–100.37 98.83–100.15
Precision (RSD,a %)
Intra-day precision (n= 3) 0.23–1.28 0.39–1.07
Inter-day precision (n= 3) 0.12–1.46 0.22–1.54
Repeatability study (n= 6) 0.45 0.63
a RSD is relative standard deviation and ‘n’ is number of
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240 lg/mL) and FAM (0, 2.5, 5, 7.5 lg/mL) were added to a
pre quantiﬁed sample solution, and the amount of IBU and
FAM was estimated by measuring derivative response at the
appropriate wavelengths. The recovery was veriﬁed by the esti-
mation of drugs in triplicate preparations at each speciﬁed
concentration levels.
2.3.4.2. Precision. The repeatability (intra-day) and intermedi-
ate precision (inter-day) study of the proposed ﬁrst derivative
spectrophotometery method were carried by estimating the
corresponding derivative responses three times on the same
day and on 3 different days (ﬁrst, second, third day) for three
different concentrations of IBU (100, 400, 600 lg/mL) and
FAM (5, 10, 25 lg/mL), and the results are reported in terms
of relative standard deviation (RSD).
The repeatability studies were carried out by analyzing IBU
(300 lg/mL) and FAM (10 lg/mL) six times and results are re-
ported in terms of relative standard deviation.
2.3.4.3. Speciﬁcity. For speciﬁcity study commonly used excip-
ients present in selected tablet formulation were spiked into a
pre weighed quantity of drugs. The absorbance was measured
and the quantities of drugs were determined. The excipients
used were talc, micro crystalline cellulose, starch (S.D. Fine
Chemicals, India) and carboxy methyl cellulose (Allied Chem-
ical Corporation, India).
2.3.4.4. Robustness. Robustness of the method was studied by
observing the stability of both the drug solutions at 25 ± 2 C
for 24 h.
2.3.5. Laboratory prepared mixtures
Appropriate aliquots of IBU working standard solutions were
taken in different 10 mL volumetric ﬂasks. To the same ﬂask
appropriate aliquots of FAM working standard solutions were
added and the volume was diluted to the mark with methanol
to achieve ﬁnal concentration of 100, 200, 400, 600 lg/mL of
IBU and 5, 10, 20, 25 lg/mL of FAM.
Spectra of the solutions were scanned and corresponding
second order derivative responses were measured at 272.8 nm
and 290 nm.Figure 2 Zero order overlay spectra of ibuprofen and
famotidine.
determinations.2.3.6. Analysis of marketed formulations
Twenty tablets were weighed accurately and ﬁnely powdered.
Tablet powder equivalent to 800 mg IBU (and 26.6 mg of
FAM) was taken in a 100 ml volumetric ﬂask. Methanol
(50 ml) was added to the above ﬂask and the ﬂask was soni-
cated for 10 min. The solution was ﬁltered using Whatman ﬁl-
ter paper No. 41 and the volume was made up to the mark
with the methanol.
Appropriate volume of the aliquot was transferred to a
10 ml volumetric ﬂask and the volume was made up to the mark
with the methanol to obtain a solution containing 320 lg/mL of
IBU and 10.64 lg/mL of FAM. The solution was sonicated for
10 min. The absorbances were noted at respective wavelength.
The amounts of IBU and FAM were determined by ﬁtting
the derivative responses into the equation of straight line repre-
senting the calibration curves for IBU and FAM.
Table 3 Determination of NEB and HCTZ in laboratory
prepared mixtures by proposed ﬁrst order derivative spectro-
photometery and LC method.
Sr. No. IBU FAM
Amt. takena % found ± SDb Amt. takena % found ± SDb
1 100 97.14 ± 0.92 5 99.71 ± 1.03
2 200 99.34 ± 1.78 10 98.45 ± 0.82
3 400 98.56 ± 0.47 20 101.12 ± 1.15
4 600 98.45 ± 1.28 25 97.62 ± 1.53
a Amount of drug taken in lg/mL.
b Average of three determinations; SD = standard deviation.
Table 4 Analysis of marketed formulation.
Formulations Labeled amount (mg) % Recoverya
IBU FAM IBU FAM
A 800 26.6 99.81 ± 0.72 99.56 ± 1.37
a Mean value ± standard deviation of three determinations;
tablet formulation A is DUEXIS (Horizon Pharma, USA) con-
taining labeled amount of 800 mg of ibuprofen and 26.6 mg of
famotidine.
S108 D.A. Shah et al.3. Results and discussion
3.1. Derivative spectrophotometric method
Fig. 2 shows overlaid zero order spectra of IBU and FAM in
methanol. FAM signiﬁcantly contributes to the absorbance of
IBU at the maximum absorbance value so, derivative method
was selected for the estimation of IBU and FAM in the pres-
ence of each other. The second order derivative spectra (D2)
of IBU and FAM showed a ZCPs of IBU at 290 nm where
FAM gives signiﬁcant derivative response, while the D2 spec-
trum of FAM has zero absorbance at 272.8 nm where IBU
gives signiﬁcant derivative response (Fig. 3). The ZCPs of both
the drugs remained constant and no shift was observed. There-
fore, 272.8 nm was selected for the estimation of IBU and
290 nm was selected for the estimation of FAM.
With an increase in the concentration of IBU, the derivative
response at 272.8 nm increased. The responses for IBU were
found to be linear in the concentration range of 100–600 lg/
mL, with a correlation coefﬁcient of 0.9992. Similarly, the
derivative responses for FAM at 290 nm were linear in the con-
centration range of 5–25 lg/mL with r= 0.9990. The regres-
sion analysis of the calibration curves is shown in Table 1.
The recoveries of IBU and FAM were found to be in the
range of 99.86–100.37% and 98.83–100.15%, respectively,
which are satisfactory. Precision studies were carried out to
study the intra-day and inter-day variability of the responses.
The low RSD value indicates that the method is precise (Table
2). Excipients used in the speciﬁcity studies did not interfere
with the derivative response of either of the drugs at their
respective analytical wavelengths. In robustness study, no sig-
niﬁcant change in the derivative response of both the drugs
was observed after 24 h and the percentage recovery for IBUand FAM were found to be more than 98% for both the drugs.
The validation parameters are summarized in Table 2.
The proposed method was valid for the determination of
IBU and FAM in different laboratory prepared mixtures with
mean recoveries as shown in Table 3. The mean recoveries
indicate that the method is accurate and precise.
The proposed method was applied for the determination of
IBU and FAM in their combined tablet dosage forms. The re-
sults obtained were comparable with the corresponding labeled
amounts (Table 4).
4. Conclusion
A second order derivative spectrophotometery method has
been developed for the estimation of IBU and FAM in their
combined dosage form. The method was validated and found
to be simple, sensitive, accurate and precise. Second order
derivative spectrophotometric method is having advantages
that it is simple, requires less analysis time and the cost of anal-
ysis is less compared to chromatographic method. The method
was successfully applied in the estimation of IBU and FAM in
their combined dosage form.Acknowledgements
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